Posted by ABMN Staff on Mar 19th, 2024
Wedbush reissued their outperform rating on shares of Geron (NASDAQ:GERN – Free Report) in a report issued on Friday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the biopharmaceutical company’s...
More of this article »